The hypothalamic-pituitary-thyroid (HPT) axis controls thyroid gland activity, functioning as a negative-feedback loop. Thyrotropin-releasing hormone (TRH) is secreted by the hypothalamus into the pituitary circulation, where it stimulates the secretion of thyrotropin (TSH). TSH is secreted into the general circulation and travels to the thyroid gland, where it stimulates production of the iodinated hormones thyroxine (T 4 ) and triiodothyronine (T 3 ). T 4 and T 3 circulate throughout the body, affecting metabolic processes in many organs. T 4 and T 3 also travel back to the hypothalamus and pituitary, suppressing the secretion of TRH and TSH, thereby completing the negative-feedback loop. TRH cannot be accurately measured in the circulation, but sensitive and accurate assays exist for TSH, T 4 , and T 3 .
inside the cell, the free T 3 binds to a specific nuclear receptor, and the complex binds to DNA and exerts metabolic effects by altering DNA transcription. T 4 is less active in binding DNA and is primarily a prohormone for T 3 synthesis.
Tests of the Thyroid Axis
Total (protein bound plus free) T 4 and T 3 levels are measured by competitive immunoassays. Because almost all T 4 and T 3 are protein bound, total T 4 and T 3 assays essentially measure inactive thyroid hormone levels. Total T 4 and T 3 levels can be abnormal due to alterations in the amount or affinity of the thyroid hormone-binding proteins, the most important of which is thyroxine-binding globulin (TBG). 1 Free (active) T 4 and T 3 levels are normal in these cases, and there is no thyroid problem. However, the abnormal total T 4 or T 3 levels can suggest to the physician that there is a problem, leading to unnecessary testing or treatment. For this reason, if a total T 4 or T 3 level is measured, it must be interpreted in conjunction with some measure of thyroid hormone binding (ie, T 3 resin uptake or TBG levels).
This problem can be circumvented by the direct measurement of free T 4 or T 3 levels. A number of assays, all based on competitive immunoassay techniques, measure free thyroid hormone levels. 2 The gold standard free thyroid hormone assay is direct equilibrium dialysis, which should be performed if results from indirect or analog free T 4 or free T 3 assays do not fit the clinical presentation.
Assessment of free T 4 levels is appropriate in the evaluation of thyroid disease. In contrast, total or free T 3 levels are not usually helpful, since most T 3 is produced in the periphery. An exception would be a patient with a suppressed TSH level but a normal free T 4 level; in this case, the total or free T 3 level should be measured. 3 An elevated free T 3 value indicates hyperthyroidism (T 3 toxicosis), which requires treatment. Aside from this indication, there is little reason to obtain total or free T 3 levels.
Sensitive and specific sandwich immunoassays for TSH, now commonly used, have supplanted older radioimmunoassays. 4 Because TSH plays a central role in the HPT axis, any perturbation in thyroid hormone levels leads to reciprocal changes in TSH secretion. Based on this relationship, a single TSH measurement is sufficient to screen for thyroid disease in most cases. Exceptions to this rule include rare patients with pituitary or hypothalamic disease (in whom the negative-feedback loop is disrupted), patients with severe illness (who have low TSH levels due to the illness), and patients who are undergoing treatment for hyperthyroidism (in whom the suppressed TSH may take months to recover to normal levels).
Thyroglobulin (Tg) is a glycoprotein synthesized by thyroid cells and cosecreted with thyroid hormones. Measurement of Tg (usually by immunometric assay) is occasionally helpful in evaluating causes of hyperthyroidism. However, it is most often used as a tumor marker for differentiated thyroid cancer. 
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In patients who have been cured of thyroid cancer, Tg levels should usually be undetectable, and any measurable Tg suggests tumor persistence or recurrence. Tg is most sensitive if measured under TSH stimulation, when the patient is hypothyroid, or following recombinant TSH administration.
There are a number of technical problems with Tg assays. 5 One problem is the presence of anti-Tg antibodies, produced by 30% of patients with thyroid cancer, which renders most Tg assays uninterpretable. Anti-Tg antibodies should always be measured with Tg levels to avoid erroneous treatment decisions. Another problem is a lack of concordance among different Tg assays, which means that long-term follow-up of patients with thyroid cancer requires serial assessment of Tg levels by the same assay.
Antithyroid antibodies (antithyroid peroxidase and anti-Tg) are often present in patients with autoimmune thyroid disease and can be quantitated by standard assays. 6 However, they have limited utility since many healthy people without clinical thyroid disease have positive antithyroid antibodies, and many patients with obvious autoimmune thyroid disease have negative antibodies.
Use of Laboratory Tests in Thyroid Disease Hypothyroidism
Hypothyroidism occurs when the thyroid gland produces insufficient T 4 to meet the body's metabolic needs. Typical symptoms include weight gain, cold intolerance, dry skin and hair, constipation, depression, and menstrual disturbances. Almost all cases of hypothyroidism are due to primary thyroid gland failure, although a rare patient has hypothyroidism due to pituitary or hypothalamic disease. The most common cause of primary hypothyroidism is autoimmune thyroid gland failure, or Hashimoto thyroiditis. 7 Other causes include late sequelae of treatment for hyperthyroidism, subacute or silent thyroiditis, radiation or surgery to the neck, and certain medications.
When the thyroid gland begins to fail, the initial indication is a rise in TSH level, which occurs before free T 4 levels fall below the normal range. This early or mild hypothyroidism is called "subclinical hypothyroidism," although studies suggest that this condition is not subclinical but leads to adverse effects on lipid levels, cardiac function, and neurocognitive function. 8 As the hypothyroidism progresses, free T 4 levels decline to below the normal range, and the patient develops overt hypothyroidism. Serum total and free T 3 levels are maintained in the normal range until the patient has severe hypothyroidism; thus, levels are not helpful for diagnosis.
Clinicians should have a low threshold for screening patients for hypothyroidism, because the condition is common and the symptoms are often vague. The appropriate screening test is a TSH measurement, unless the physician suspects hypothyroidism due to a pituitary or hypothalamic problem. If the TSH level is elevated, free T 4 should be measured. If the free T 4 is low, the patient has overt hypothyroidism and requires treatment with replacement doses of Lthyroxine (L-T 4 ). If the free T 4 level is normal, the patient has subclinical hypothyroidism and the TSH should be reassessed in 2 to 3 months to exclude transient causes of TSH elevation. If the TSH remains elevated, most thyroid specialists recommend treatment with low doses of L-T 4 . In treating hypothyroidism, the goal is to achieve a normal TSH level. When L-T 4 therapy is started or the dosage is changed, TSH should be remeasured at least 4 weeks later to assess adequacy of dosage. Misleading TSH results will be obtained if the TSH is measured sooner, since the HPT axis has not reequilibrated after the dose adjustment.
Hyperthyroidism
Hyperthyroidism occurs when the thyroid produces too much T 4 or T 3 for the body's metabolic needs. Symptoms include increased appetite, weight loss, diarrhea, sweating, heat intolerance, palpitations, nervousness, tremor, difficulty sleeping, and menstrual disturbances. Almost all hyperthyroidism is due to thyroid gland problems, although the rare patient has a pituitary problem. The most common cause is Graves disease, which is due to thyroid gland stimulation by autoantibodies that mimic TSH. 9 Other causes include toxic adenomas, toxic multinodular goiter, subacute or silent thyroiditis, and certain medications.
When the thyroid gland becomes overactive, the initial indication is a suppression of TSH levels, which occurs before free T 4 or free T 3 levels rise above the normal range. This early or mild hyperthyroidism is called subclinical hyperthyroidism, although studies suggest that this condition is not subclinical but leads to adverse effects on cardiac, bone, and neurocognitive function. 8 As the hyperthyroidism progresses, free T 4 levels increase above the normal range, and the patient develops overt hyperthyroidism. In some cases, the overactive thyroid produces more T 3 than T 4 , and T 3 toxicosis develops, with elevated levels of total and free T 3 .
The appropriate screening test for suspected hyperthyroidism is a TSH assessment, unless the physician suspects hyperthyroidism due to a pituitary problem. If the TSH is suppressed (below the assay detection limit), a free T 4 should be measured. If the free T 4 is high, the patient has overt hyperthyroidism and requires treatment. If the free T 4 is normal, a total or free T 3 level should be checked to exclude T 3 toxicosis. If both the free T 4 and T 3 are normal, the patient has subclinical hyperthyroidism, and the TSH should be reassessed in 2 to 3 months to exclude transient causes of TSH suppression. If the TSH remains suppressed, a clinical decision must be made to treat the subclinical hyperthyroidism or to monitor without treatment, depending on the patient's risk factors. It should also be noted that many patients who are ill with other diseases or taking certain medications may have low but detectable TSH levels. This is not subclinical hyperthyroidism but rather an entity called nonthyroidal illness. 4 Options for treatment of hyperthyroidism include radioactive iodine, which is effective but usually leads to hypothyroidism, or antithyroid drugs, which are effective, but often do not lead to cure. Another option for some patients is thyroid surgery. laboratorymedicine> may 2001> number 5> volume 32
Thyroid Goiter, Nodules, and Thyroid Cancer
Enlargement of the thyroid gland (goiter), which is common, can be diffuse or consist of 1 or more nodules. Because any type of thyroid enlargement can be associated with normal or altered thyroid function, a patient with an abnormal thyroid gland should first undergo TSH level assessment. Patients with hypothyroidism or hyperthyroidism undergo testing and are treated as outlined in the previous section. Euthyroid patients with goiters are usually observed without treatment unless the goiter itself is causing symptoms. Euthyroid patients with single, large, or suspicious nodules should undergo fineneedle aspiration biopsy of the nodule to rule out cancer. In the past, many benign goiters and thyroid nodules were treated with L-T 4 suppression therapy, but studies have shown that this is not especially effective and leads to possible long-term adverse effects on the heart and bone.
Approximately 5% of thyroid nodules are shown to contain thyroid cancer at surgery. 10 Most cases of thyroid cancer are best treated with a combination of surgery, radioactive iodine, and L-T 4 therapy. In this case, L-T 4 is administered at doses that suppress TSH to low levels, since TSH acts a growth factor for thyroid cancer. Patients are observed with assessment of thyroid hormone levels and Tg levels and the use of radioactive iodine whole-body scans to detect residual or recurrent disease. 10
